Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000804693 | SCV000944614 | uncertain significance | RYR1-related disorder | 2022-06-04 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 3185 of the RYR1 protein (p.Lys3185Asn). This variant is present in population databases (rs201080180, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with RYR1-related conditions. ClinVar contains an entry for this variant (Variation ID: 649704). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV001310409 | SCV001500196 | uncertain significance | not provided | 2020-10-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002487717 | SCV002788326 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-09-25 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001310409 | SCV003813059 | uncertain significance | not provided | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003258980 | SCV003979730 | uncertain significance | Inborn genetic diseases | 2023-03-20 | criteria provided, single submitter | clinical testing | The c.9555G>C (p.K3185N) alteration is located in exon 65 (coding exon 65) of the RYR1 gene. This alteration results from a G to C substitution at nucleotide position 9555, causing the lysine (K) at amino acid position 3185 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV003514415 | SCV004358171 | uncertain significance | Malignant hyperthermia, susceptibility to, 1 | 2023-11-13 | criteria provided, single submitter | clinical testing | This missense variant replaces lysine with asparagine at codon 3185 of the RYR1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.6, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with RYR1-related disorders in the literature. This variant has been identified in 32/184170 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |